D‐512, a novel dopamine D(2/3) receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats

BACKGROUND AND PURPOSE: Symptoms of Parkinson's disease are commonly managed using selective dopamine D(2/3) receptor agonists, including ropinirole. While D(2/3) agonists are useful in early‐stage Parkinson's disease, they tend to lose efficacy in later disease stages and do not appear to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Pharmacol
Hauptverfasser: Lindenbach, David, Das, Banibrata, Conti, Melissa M, Meadows, Samantha M, Dutta, Aloke K, Bishop, Christopher
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Research Papers
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573415/
https://ncbi.nlm.nih.gov/pubmed/28667675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13937
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge